BioCentury
ARTICLE | Company News

Borean, Roche deal

May 15, 2006 7:00 AM UTC

Borean granted ROCZ exclusive rights to develop and commercialize Trimeric Apo A-I to treat atherosclerosis. The trimerized version of the naturally occurring apolipoprotein A-I (Apo A-I) is entering...